中国新药杂志

Toll样受体在慢性疾病中的研究进展

PDF下载

张铭露 , 吴彦霖 , 张媛 , 高华

中国新药杂志 | 重大新药创制专项巡礼 2021,30(3): 215-219

收起

中国新药杂志 |重大新药创制专项巡礼 2021 , 30 (3) : 215 -219

Toll样受体在慢性疾病中的研究进展

全屏

[Author(id=1322627037626479072, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=zhangminglu9@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322627037706170850, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, authorId=1322627037626479072, language=EN, stringName=Ming-lu ZHANG, firstName=Ming-lu, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=National Institutes for Food and Drug Control, Beijing 102629, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322627037781668323, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, authorId=1322627037626479072, language=CN, stringName=张铭露, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国食品药品检定研究院，北京　102629, bio={"content":"

张铭露，女，硕士研究生，主要从事药检药理研究。E-mail：zhangminglu9@163.com。

"}, bioImg=null, bioContent=

张铭露，女，硕士研究生，主要从事药检药理研究。E-mail：zhangminglu9@163.com。

吴彦霖，女，博士，副研究员，主要从事药检药理研究。联系电话：（010）53851590，E-mail：wyljoe@126.com。

"}, bioImg=null, bioContent=

吴彦霖，女，博士，副研究员，主要从事药检药理研究。联系电话：（010）53851590，E-mail：wyljoe@126.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322627037530010076, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, xref=null, ext=[AuthorCompanyExt(id=1322627037538398685, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, companyId=1322627037530010076, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Institutes for Food and Drug Control, Beijing 102629, China), AuthorCompanyExt(id=1322627037550981598, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, companyId=1322627037530010076, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国食品药品检定研究院，北京　102629)])]), Author(id=1322627038125601258, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322627038192710124, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, authorId=1322627038125601258, language=EN, stringName=Yuan ZHANG, firstName=Yuan, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=National Institutes for Food and Drug Control, Beijing 102629, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322627038259818989, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, authorId=1322627038125601258, language=CN, stringName=张媛, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国食品药品检定研究院，北京　102629, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322627037530010076, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, xref=null, ext=[AuthorCompanyExt(id=1322627037538398685, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, companyId=1322627037530010076, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Institutes for Food and Drug Control, Beijing 102629, China), AuthorCompanyExt(id=1322627037550981598, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, companyId=1322627037530010076, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国食品药品检定研究院，北京　102629)])]), Author(id=1322627038352093679, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=huag55@163.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322627038440174065, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, authorId=1322627038352093679, language=EN, stringName=Hua GAO, firstName=Hua, middleName=null, lastName=GAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=National Institutes for Food and Drug Control, Beijing 102629, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322627038507282930, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, authorId=1322627038352093679, language=CN, stringName=高华, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国食品药品检定研究院，北京　102629, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322627037530010076, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, xref=null, ext=[AuthorCompanyExt(id=1322627037538398685, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, companyId=1322627037530010076, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Institutes for Food and Drug Control, Beijing 102629, China), AuthorCompanyExt(id=1322627037550981598, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627036837949913, companyId=1322627037530010076, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国食品药品检定研究院，北京　102629)])])]

张铭露, 吴彦霖, 张媛, 高华

作者信息

中国食品药品检定研究院，北京　102629

通讯作者:

高华，女，博士，研究员，主要从事药检药理研究。联系电话：（010）53851589，E-mail：huag55@163.com。

作者简介:

张铭露，女，硕士研究生，主要从事药检药理研究。E-mail：zhangminglu9@163.com。

吴彦霖，女，博士，副研究员，主要从事药检药理研究。联系电话：（010）53851590，E-mail：wyljoe@126.com。

Research progress of Toll-like receptors in chronic diseases

Ming-lu ZHANG, Yan-lin WU, Yuan ZHANG, Hua GAO

Affiliations

National Institutes for Food and Drug Control, Beijing 102629, China

出版时间: 2021-02-15

文章导航

摘要

收起

Toll样受体（Toll-like receptor，TLRs）是免疫系统参与活化炎症反应的初始应答者之一，TLRs主要参与的是非特异性免疫和炎症反应。有研究表明，TLRs是多种慢性疾病（癌症、非酒精性脂肪肝、慢性阻塞性肺疾病、心血管疾病以及神经退行性疾病等）相关发展的激活因子，并在其疾病的发展中起着十分重要的作用。本文主要对TLRs在上述这些主要的慢性疾病中的作用进行综述。

关键词

Toll样受体 / 炎症 / 慢性疾病 / 天然产物

Abstract

收起

Toll-like receptors (TLRs) are one of the initial responders of immune system involved in the activation of inflammatory responses. TLRs are mainly involved in non-specific immune and inflammatory responses. Studies have shown that TLRs act as activating factors in the development of a variety of chronic diseases (cancer, nonalcoholic fatty liver disease, chronic obstructive pulmonary disease, cardiovascular disease and neurodegenerative diseases), and play a very important role in the development of the diseases. This article reviews the role of TLRs in these major chronic diseases.

Key words

Toll-like receptor / inflammation / chronic disease / natural products

引用本文

张铭露, 吴彦霖, 张媛, 高华. Toll样受体在慢性疾病中的研究进展. 中国新药杂志, 2021 , 30 (3) : 215 -219 .

Ming-lu ZHANG, Yan-lin WU, Yuan ZHANG, Hua GAO. Research progress of Toll-like receptors in chronic diseases[J]. Chinese Journal of New Drugs, 2021 , 30 (3) : 215 -219 .

基金

收起

国家“重大新药创制”科技重大专项资助项目(2018ZX09101001-003-005)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

PACHATHUNDIKANDI SK, LIND J, TEGTMEYER N, et al. Interplay of the gastric PathogenHelicobacter pyloriwith toll-like receptors[J]. Biomed Res Int, 2015, 2015: 1-12.

[2]

ADEREM A, ULEVITCH RJ. Toll-like receptors in the induction of the innate immune response[J]. Nature, 2000, 406(6797): 782-787.

[3]

VIDYA MK, KUMAR VG, SEJIAN V, et al. Toll-like receptors: Significance, ligands, signaling pathways, and functions in mammals[J]. Int Rev Immunol, 2018, 37(1): 20-36.

[4]

YU L, WANG L, CHEN S. Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis?[J]. Cell Mol Life Sci, 2012, 69(6): 935-949.

[5]

LARSEN PH, HOLM TH, OWENS T. Toll-like receptors in brain development and homeostasis[J]. Sci STKE, 2007, 2007(402): pe47.

[6]

MICHELSEN KS, ARDITI M. Toll-like receptors and innate immunity in gut homeostasis and pathology[J]. Curr Opin Hematol, 2007, 14(1): 48-54.

[7]

RAKOFF-NAHOUM S, MEDZHITOV R. Toll-like receptors and cancer[J]. Nat Rev Cancer, 2009, 9(1): 57-63.

[8]

VINITA, MISHRA, CHANDRAMANI, et al. Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer[J]. International Journal of Biological Macromolecules, 2019; 122: 425-451.

[9]

TONGTAWEE T, SIMAWARANON T, WATTANAWONGDON W, et al. Toll-like receptor 2 and 4 polymorphisms associated with Helicobacter pylori susceptibility and gastric cancer[J]. The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology, 2019, 30(1): 15-20.

[10]

CHEN J, HU S, LIANG SH, et al. Associations between the four toll-like receptor polymorphisms and the risk of gastric cancer: a meta-analysis[J]. Cancer Biotherapy Radiopharm, 2013, 28(9): 674-681.

[11]

SHENG WY, YONG Z, YUN Z, et al. Systematic review/Meta-analysis Toll-like receptor 4 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review[J]. Aoms, 2015, 4: 699-707.

[12]

TIAN SJ, ZHANG LP, YANG T, et al. The associations between toll-like receptor 9 gene polymorphisms and cervical cancer susceptibility[J]. Mediat Inflamm, 2018, 2018: 1-11.

[13]

WANG W, WANG J. Toll-like receptor 4 (TLR4)/cyclooxygenase-2 (COX-2) regulates prostate cancer cell proliferation, migration, and invasion by NF-κB activation[J]. Med Sci Monit, 2018, 24: 5588-5597.

[14]

SUN M, GENG D, LI S, et al. LncRNA PART1 modulates toll-like receptor pathways to influence cell proliferation and apoptosis in prostate cancer cells[J]. Biol Chem, 2018, 399(4): 387-395.

[15]

WANG LL, ZHU R, HUANG ZQ, et al. Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma[J]. Dig Dis Sci, 2013, 58(8): 2223-2236.

[16]

ZU YK, PING W, DENG TR, et al. Lipopolysaccharide-induced toll-like receptor 4 signaling in esophageal squamous cell carcinoma promotes tumor proliferation and regulates inflammatory cytokines expression[J]. Dis Esophagus, 2017, 30(2): 1-8.

[17]

MESEURE D, VACHER S, DRAK ALSIBAI K, et al. Biopathological significance of TLR9 expression in cancer cells and tumor microenvironment across invasive breast carcinomas subtypes[J]. Cancer Microenviron, 2016, 9(2-3): 107-118.

[18]

RUAN M, ZHANG Z, LI SY, et al. Increased expression of Toll-like receptor-9 has close relation with tumour cell proliferation in oral squamous cell carcinoma[J]. Arch Oral Biol, 2011, 56(9): 877-884.

[19]

MATIJEVIC GT, CIPAK GA, VÉRILLAUD B, et al. Toll-like receptor 3 stimulation triggers metabolic reprogramming in pharyngeal cancer cell line through Myc, MAPK, and HIF[J]. Mol Carcinog, 2017, 56(4): 1214-1226.

[20]

CHEN S, YUAN WG, FU ZK, et al. Toll-like receptor 5 gene polymorphism is associated with breast cancer susceptibility[J]. Oncotarget, 2017, 8(51): 88622-88629.

[21]

WANG F, JIN R, ZOU BB, et al. Activation of Toll-like receptor 7 regulates the expression of IFN-λ1, p53, PTEN, VEGF, TIMP-1 and MMP-9 in pancreatic cancer cells[J]. Mol Med Rep, 2016, 13(2): 1807-1812.

[22]

NARAYANANKUTTY A. Toll-like receptors as a novel therapeutic target for natural products against chronic diseases[J]. Curr Drug Targets, 2019, 20(10): 1068-1080.

[23]

BHAGAT L, WANG DQ, JIANG WW, et al. Abstract 2570: IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: a potential novel approach for treatment of B-cell lymphomas harboring MYD88 L265P mutation[C].2014.

[24]

BENEDICT M, ZHANG XC. Non-alcoholic fatty liver disease: an expanded review[J]. World J Hepatol, 2017, 9(16): 715-732.

[25]

ASRIH M, JORNAYVAZ FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance[J]. J Endocrinol, 2013, 218(3): R25-R36.

[26]

JIA L, CHANG XL, QIAN SW, et al. Hepatocyte toll-like receptor 4 deficiency protects against alcohol-induced fatty liver disease[J]. Mol Metab, 2018, 14: 121-129.

[27]

MATSUSHITA H, ROH YS, KIYANI A, et al. 647 TLR7 signaling as potential therapeutic target for mouse model of alcoholic hepatitis[J]. Gastroenterology, 2015, 148(Suppl 4): S989.

[28]

PANG S, TANG H, ZHUO S, et al. Regulation of fasting fuel metabolism by toll-like receptor 4[J]. Diabetes, 2010, 59(12): 3041-3048.

[29]

KIM S, PARK S, KIM B, et al. Toll-like receptor 7 affects the pathogenesis of non-alcoholic fatty liver disease[J]. Sci Rep, 2016, 6: 27849.

[30]

ETIENNE-MESMIN L, VIJAY-KUMAR M, GEWIRTZ AT, et al. Hepatocyte toll-like receptor 5 promotes bacterial clearance and protects mice against high-fat diet-induced liver disease[J]. Cell Mol Gastroenterol Hepatol, 2016, 2(5): 584-604.

[31]

徐瑞, 黄鹏, 张祎冰, 等. p38MAPK在动脉粥样硬化机制中的研究进展[J]. 中国老年学杂志, 2019, 39(17): 4365-4368.

[32]

FAVA C, MONTAGNANA M. Atherosclerosis is an inflammatory disease which lacks a common anti-inflammatory therapy: how human genetics can help to this issue. A narrative review[J]. Front Pharmacol, 2018, 9: 55. DOI: 10.3389/fphar.2018.00055.

[33]

PARIZADEH SM, GHANDEHARI M, HEYDARI-MAJD M, et al. Toll-like receptors signaling pathways as a potential therapeutic target in cardiovascular disease[J]. Curr Pharm Des, 2018, 24(17): 1887-1898.

[34]

YANG SS, LI RG, TANG L, et al. TLR4-mediated anti-atherosclerosis mechanisms of angiotensin-converting enzyme inhibitor-Fosinopril[J]. Cell Immunol, 2013, 285(1-2): 38-41.

[35]

ELLENBROEK GH, VAN PUIJVELDE GH, ANAS AA, et al. Leukocyte TLR5 deficiency inhibits atherosclerosis by reduced macrophage recruitment and defective T-cell responsiveness[J]. Sci Rep, 2017, 7: 42688.

[36]

MEYER I, MARTINET W, SCHRIJVERS DM, et al. Toll-like receptor 7 stimulation by imiquimod induces macrophage autophagy and inflammation in atherosclerotic plaques[J]. Basic Res Cardiol, 2012, 107(3): 1-13.

[37]

MADAN M, AMAR S. Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic findings[J]. PLoS One, 2008, 3(9): e3204.

[38]

SALAGIANNI M, GALANI IE, LUNDBERG AM, et al. Toll-like receptor 7 protects from atherosclerosis by constraining “inflammatory” macrophage activation[J]. Circulation, 2012, 126(8): 952-962.

[39]

KOULIS C, CHEN YC, HAUSDING C, et al. Protective role for toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice[J]. Arterioscler Thromb Vasc Biol, 2014, 34(3): 516-525.

[40]

HANSEL TT, BARNES PJ. New drugs for exacerbations of chronic obstructive pulmonary disease[J]. Lancet, 2009, 374(9691): 744-755.

[41]

BAINES KJ, SIMPSON JL, GIBSON PG. Innate immune responses are increased in chronic obstructive pulmonary disease[J]. PLoS One, 2011, 6(3): e18426.

[42]

WORTHAM BW, EPPERT BL, FLURY JL, et al. TLR and NKG2D signaling pathways mediate CS-induced pulmonary pathologies[J]. PLoS One, 2013, 8(10): e78735.

[43]

ZUO L, LUCAS K, FORTUNA CA, et al. Molecular regulation of toll-like receptors in asthma and COPD[J]. Front Physiol, 2015, 6: 312.

[44]

孟莹, 余常辉, 李婷, 等. Toll样受体4在烟熏和脂多糖联合烟熏所致肺损伤大鼠中的表达及意义[J]. 中华医学杂志, 2013, 93(28): 2230-2234.

[45]

MCGEER EG, MCGEER PL. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy[J]. J Alzheimer's Dis, 2010, 19(1): 355-361.

[46]

JOSHI N, SINGH S. Updates on immunity and inflammation in Parkinson disease pathology[J]. J Neurosci Res, 2018, 96(3): 379-390.

[47]

XIANG W, CHAO ZY, FENG DY. Role of Toll-like receptor/MYD88 signaling in neurodegenerative diseases[J]. Rev Neurosci, 2015, 26(4): 407-414.

[48]

SONG M, JIN JJ, LIM JE, et al. TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease[J]. J Neuroinflammation, 2011, 8(1): 1-14.

[49]

QIN Y, LIU Y, HAO W, et al. Stimulation of TLR4 attenuates Alzheimer's disease-related symptoms and pathology in tau-transgenic mice[J]. J Immunol, 2016, 197(8): 3281-3292.

[50]

HUANG NQ, JIN H, ZHOU SY, et al. TLR4 is a link between diabetes and Alzheimer's disease[J]. Behav Brain Res, 2017, 316: 234-244.

[51]

MCDONALD CL, HENNESSY E, RUBIO-ARAIZ A, et al. Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer's disease[J]. Brain Behav Immun, 2016, 58: 191-200.

[52]

CHAKRABARTY P, LI A, LADD TB, et al. TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease[J]. J Exp Med, 2018, 215(9): 2247-2264.

[53]

SCHOLTZOVA H, KASCSAK RJ, BATES KA, et al. Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology[J]. J Neurosci, 2009, 29(6): 1846-1854.

[54]

ZHU KH, TENG JJ, ZHAO J, et al. Association of TLR9 polymorphisms with sporadic Parkinson's disease in Chinese Han population[J]. Int J Neurosci, 2015, 2015: 1-5.

[55]

DZAMKO N, GYSBERS A, PERERA G, et al. Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology[J]. Acta Neuropathol, 2017, 133(2): 303-319.

[56]

CHAHAL DS, SIVAMANI RK, RIVKAH ISSEROFF R, et al. Plant-based modulation of toll-like receptors: an emerging therapeutic model[J]. Phytother Res, 2013, 27(10): 1423-1438.

[57]

ILLAM SP, NARAYANANKUTTY A, MATHEW SE, et al. Epithelial mesenchymal transition in cancer progression: prev entive phytochemicals[J]. Recent Patents Anti-Cancer Drug Discov, 2017, 12(3): 234-246.

[58]

BAGAD AS, JOSEPH JA, BHASKARAN N, et al. Comparative evaluation of anti-inflammatory activity of curcuminoids, turmerones, and aqueous extract of Curcuma longa[J]. Adv Pharmacol Sci, 2013, 2013: 805756.

[59]

RANA M, MAURYA P, REDDY SS, et al. A standardized chemically modified Curcuma longa extract modulates IRAK-MAPK signaling in inflammation and potentiates cytotoxicity[J]. Front Pharmacol, 2016, 7: 223.

[60]

TU CT, YAO QY, XU BL, et al. Protective effects of curcumin against hepatic fibrosis induced by carbon tetrachloride: Modulation of high-mobility group box 1, Toll-like receptor 4 and 2 expression[J]. Food Chem Toxicol, 2012, 50(9): 3343-3351.

[61]

任强, 李小梅, 刘泽玉. 姜黄素对脓毒症大鼠肠损伤作用效果及其相关信号通路和机制研究[J]. 世界临床药物, 2020, 41(11): 36-40.

[62]

CHEN X, CHANG L, QU Y, et al. Tea polyphenols inhibit the proliferation, migration, and invasion of melanoma cells through the down-regulation of TLR4[J]. Int J Immunopathol Pharmacol, 2018, 32: 394632017739531.

[63]

LI JH, SASAKI GY, DEY P, et al. Green tea extract protects against hepatic NFκB activation along the gut-liver axis in diet-induced obese mice with nonalcoholic steatohepatitis by reducing endotoxin and TLR4/MyD88 signaling[J]. J Nutr Biochem, 2018, 53: 58-65.

2021年第30卷第3期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-29
出版时间：2021-02-15

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-04-13

基金

国家“重大新药创制”科技重大专项资助项目(2018ZX09101001-003-005)

作者信息

中国食品药品检定研究院，北京　102629

通讯作者:

高华，女，博士，研究员，主要从事药检药理研究。联系电话：（010）53851589，E-mail：huag55@163.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322627036837949913

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT